Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hecera (Hecera Itch Relief Moisturising Repair Cream) is a topical, steroid-free cosmetic emollient cream developed by Rxilient Biotech and Rxilient Medical for the relief of pruritus (itching), skin redness, and skin barrier impairment. The formulation features a 5-in-1 care approach targeting itch, microbiota, redness, hydration, and skin barrier repair. Its key active components include 4-tert-butylcyclohexanol (4-TBCH), a transient receptor potential vanilloid 1 (TRPV1) antagonist that provides rapid itch relief within minutes, and Saccharide Isomerate, which delivers deep hydration for up to 72 hours. The cream is marketed for daily use in children and adults with dry, sensitive, or eczema-prone skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hecera.